COMMUNIQUÉ DE PRESSE publié le 09/01/2025 à 01:00, il y a 1 année 7 mois Onco-Innovations Provides Information Regarding Exclusive License for Patented Drug with Potential to Enhance Cancer Treatment Options Onco-Innovations Limited announces exclusive-licensed PNKP inhibitors Technology targeting cancer cells to enhance treatment effectiveness across various cancer types including colorectal, breast, and lung cancer Clinical Trials Cancer Treatment Oncology Market Onco-Innovations Limited PNKP Inhibitors Technology
Publié le 18/08/2026 à 18:00, il y a 1 jour 8 heures KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Publié le 18/08/2026 à 17:45, il y a 1 jour 9 heures Mise à disposition du rapport financier annuel 2025-26
Publié le 18/08/2026 à 11:15, il y a 1 jour 15 heures GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Publié le 18/08/2026 à 11:15, il y a 1 jour 15 heures GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Publié le 17/08/2026 à 19:45, il y a 2 jours 7 heures Aéroports de Paris S.A - July 2026 traffic figures
Publié le 20/08/2026 à 02:22, il y a 28 minutes Infrastructure Sterilisation Drilling Begins at Tunkillia
Publié le 20/08/2026 à 00:40, il y a 2 heures 10 minutes Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
Publié le 19/08/2026 à 22:00, il y a 4 heures 50 minutes Jaguar Health Reports Second Quarter 2026 Financials
Publié le 19/08/2026 à 20:35, il y a 6 heures 15 minutes Revive Therapeutics Announces Proposed Shares for Debt Settlement
Publié le 20/08/2026 à 02:44, il y a 5 minutes Quarterly Report for Q2 and Interim Consolidated Financial Statements with Notes for the period from 1 January to 30 June 2026.
Publié le 20/08/2026 à 01:45, il y a 1 heure 5 minutes EQS-Adhoc: Dexus Finance Pty Limited: 2026 Annual results – Delivers on guidance and progresses key strategic actions
